Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 24:4:160.
doi: 10.3389/fonc.2014.00160. eCollection 2014.

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting

Thomas Knight  1 , Julie Anne Elizabeth Irving  1
Affiliations
Review

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting

Thomas Knight et al. Front Oncol. .

Abstract

Deregulation of the Ras/Raf/MEK/extracellular signal-regulated kinase pathway is a common event in childhood acute lymphoblastic leukemia and is caused by point mutation, gene deletion, and chromosomal translocation of a vast array of gene types, highlighting its importance in leukemia biology. Pathway activation can be therapeutically exploited and may guide new therapies needed for relapsed acute lymphoblastic leukemia and other high risk subgroups.

Keywords: Ras/Raf/MEK/ERK pathway; acute lymphoblastic leukemia; targeted therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Regulation of Ras activity.
Figure 2
Figure 2
Mutations activating the Ras pathway in ALL and potential therapeutic targeting. Components of the pathway that are mutated in ALL are in red.
Figure 3
Figure 3
Pie chart of the frequency of Ras pathway mutations in an unselected cohort of 180 UK diagnostic ALL [data from Ref. (15, 48)].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chung E, Kondo M. Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Immunol Res (2011) 49(1–3):248–6810.1007/s12026-010-8187-5 - DOI - PubMed
    1. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 11(11):761–7410.1038/nrc3106 - DOI - PMC - PubMed
    1. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol (2012) 13(1):39–5110.1038/nrm3255 - DOI - PMC - PubMed
    1. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 120(17):3397–40610.1182/blood-2012-05-378596 - DOI - PMC - PubMed
    1. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ (2009) 16(3):368–7710.1038/cdd.2008.148 - DOI - PubMed